Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2024 08:30 ET | Source: Real Brands Inc.

Dr. Richard Goldberg Joins Real Brands' Board of Directors, Enters Consulting Agreement

North Providence, RI, May 07, 2024 (GLOBE NEWSWIRE) -- Real Brands Inc. (OTCPK: RLBD) announced today that it has added Richard J. Goldberg, MD, MS, to its Board of Directors, and The Company has...
January 13, 2023 13:00 ET | Source: GreyViews

Psychedelic Drugs Market will worth USD 6703.3 million by 2030 : GreyViews

Pune India, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle...
July 07, 2022 08:47 ET | Source: Fairfield Consultancy Services OPC Pvt Ltd

Psychedelic Drugs Market Reaches US$6330.0 Mn by 2026 from US$3210.0 Mn in 2021, at a Healthy Pace of 14.5% CAGR: Fairfield Market Research

London, July 07, 2022 (GLOBE NEWSWIRE) -- The demand for psychedelic drugs has shot up in recent years as the awareness about mental health issues reaches all classes, irrespective of age and...
July 07, 2022 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian...
July 14, 2021 16:55 ET | Source: Data Bridge Market Research

Psychedelic Drugs Market CAGR at +13.3% with Analysis of Growing Technology Trends, Industry Research, Future Growth and Size, Projection by 2028

SAN FRANCISCO, July 14, 2021 (GLOBE NEWSWIRE) -- Psychedelic Drugs Market Research Report gives insightful analysis of the market along with its comprehensive understanding and its commercial...
June 17, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all...
June 15, 2021 11:10 ET | Source: XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on...
March 29, 2021 07:02 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
March 17, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage...
February 25, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference

VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...